--- title: "U.S. stock market midday update: Radiopharm Theranostics down 14.48%, clinical benefits unable to mask losses and valuation risks" type: "News" locale: "en" url: "https://longbridge.com/en/news/294094564.md" description: "Radiopharm Theranostics fell 14.48%; AbbVie rose 3.22%, with a transaction volume of USD 717 million; Amgen rose 3.80%, with a transaction volume of USD 655 million; Gilead Sciences rose 2.21%, with a transaction volume of USD 410 million; Vertex Pharmaceuticals rose 1.24%, with a market value of USD 123.1 billion" datetime: "2026-07-28T16:48:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294094564.md) - [en](https://longbridge.com/en/news/294094564.md) - [zh-HK](https://longbridge.com/zh-HK/news/294094564.md) generator: "portal-rs" --- # U.S. stock market midday update: Radiopharm Theranostics down 14.48%, clinical benefits unable to mask losses and valuation risks **U.S. Stock Market Midday Update** Radiopharm Theranostics fell 14.48%. Based on recent key news: 1. On July 29, Radiopharm Theranostics faced pressure on its stock price due to ongoing losses and cash burn. Although the company has no debt, technical indicators remain bearish, with the stock price below key moving averages, a negative MACD, and limited valuation support due to the company not being profitable and having no dividend yield, resulting in a 14.48% drop in stock price. Source: EDGAR 2. On July 27, Radiopharm Theranostics released original content through the EDGAR system, emphasizing the company's innovative development of clinical-stage radiopharmaceuticals for tumors, covering Phase 1 and Phase 2 trials for solid tumors such as lung, breast, and brain metastases. Source: EDGAR 3. On July 28, the Securities and Exchange Commission released documents, with Radiopharm Theranostics responsible for the information, which did not provide new market impacts. Source: EDGAR The industry is facing pressure from technical indicators, with significant capital outflows. **Top Stocks by Trading Volume in the Industry** AbbVie rose 3.22%. Based on recent key news: 1. On July 28, AbbVie faces accelerated erosion risks in Humira revenue. Major pharmacy benefit management companies are shifting to interchangeable biosimilars, threatening established revenue baselines and potentially exacerbating sales losses in the immunology sector, impacting stock price increases. 2. On July 27, the U.S. stock market faced a flurry of earnings reports and policy signals, with AbbVie's earnings report influencing market expectations alongside Federal Reserve interest rate decisions and preliminary GDP estimates, potentially directing funds toward large tech stocks and interest-sensitive sectors, increasing short-term volatility. 3. On July 28, AbbVie's recent stock price increase may trigger "sell the news" volatility, but long-term holders should not be alarmed. Funds are flowing into large tech stocks, intensifying volatility. Amgen rose 3.80%. Based on recent news: 1. On July 28, market analysts rated Amgen's stock as a hold, despite five other stocks being considered better investment choices. This rating may lead some investors to reassess their portfolios, driving Amgen's stock price up. 2. On July 27, Amgen announced a new drug development plan expected to positively impact its future revenue growth. Investors reacted positively to this news, leading to a stock price increase. 3. On July 26, Amgen released a strong quarterly earnings report, showing its revenue and profits exceeded market expectations. This earnings result boosted market confidence, driving the stock price up. The biopharmaceutical industry has recently performed strongly, with noticeable capital inflows. Gilead Sciences rose 2.21%. Based on recent key news: 1. On July 28, Gilead Sciences' HIV product sales are projected to reach $20.8 billion by 2025, a 6% year-over-year increase. This growth reflects strong market demand for its product portfolio, driving the stock price up 2. On July 28, analyst ratings show that Gilead Sciences is currently rated as "Moderate Buy," but it is not listed as a top recommended stock. This indicates a cautious market attitude towards its future performance, which may affect investor confidence. 3. On July 28, GlaxoSmithKline's Dovato showed efficacy comparable to Gilead's Biktarvy in studies. This result may impact Gilead's market competitiveness, leading to stock price fluctuations. The competition in the HIV drug market is intensifying and requires attention. **Stocks ranked at the top of the industry by market capitalization** Fosun Pharma rose by 1.24%. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. no\_news ### Related Stocks - [RADX.US](https://longbridge.com/en/quote/RADX.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Radiopharm Theranostics doses first patient in second cohort of RV-01 Phase 1/2a trial in B7-H3 solid tumors](https://longbridge.com/en/news/297032752.md) - [Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock](https://longbridge.com/en/news/297831169.md) - [Michael Burry Warns of a Private Credit 'Shell Game' That Could Leave Taxpayers on the Hook: APO, KKR, OWL In Focus](https://longbridge.com/en/news/297885152.md) - [TSX Growth Stocks Insiders Are Investing In](https://longbridge.com/en/news/297784674.md) - [The 10-year Treasury yield is breaking out and 5% could be just the beginning. Here's why that matters.](https://longbridge.com/en/news/297548327.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**